Related references
Note: Only part of the references are listed.Exosomes as drug delivery vehicles for Parkinson's disease therapy
Matthew J. Haney et al.
JOURNAL OF CONTROLLED RELEASE (2015)
Extracellular vesicles as drug delivery systems: Lessons from the liposome field
Roy van der Meel et al.
JOURNAL OF CONTROLLED RELEASE (2014)
Complex interplay between the P-glycoprotein multidrug efflux pump and the membrane: its role in modulating protein function
Frances Jane Sharom
FRONTIERS IN ONCOLOGY (2014)
Intestinal drug transporters: An overview
Margarida Estudante et al.
ADVANCED DRUG DELIVERY REVIEWS (2013)
Nano scale self-emulsifying oil based carrier system for improved oral bioavailability of camptothecin derivative by P-Glycoprotein modulation
Lalit Mohan Negi et al.
COLLOIDS AND SURFACES B-BIOINTERFACES (2013)
Molecular Modeling and Ligand Docking for Solute Carrier (SLC) Transporters
Avner Schlessinger et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2013)
Enhancement effect of P-gp inhibitors on the intestinal absorption and antiproliferative activity of bestatin
Xiaokui Huo et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2013)
Mechanism of transport of saquinavir-loaded nanostructured lipid carriers across the intestinal barrier
Ana Beloqui et al.
JOURNAL OF CONTROLLED RELEASE (2013)
Core-shell-type lipid-polymer hybrid nanoparticles as a drug delivery platform
Bivash Mandal et al.
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE (2013)
Thiomer: A potential carrier for therapeutic delivery
Rakesh Kumar et al.
REACTIVE & FUNCTIONAL POLYMERS (2013)
Nanotechnological advances for the delivery of CNS therapeutics
Ho Lun Wong et al.
ADVANCED DRUG DELIVERY REVIEWS (2012)
Neurobiology of schizophrenia: from outcome to pathophysiological insights
P. Falkai et al.
EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE (2012)
Poloxamer 407/TPGS mixed micelles for delivery of gambogic acid to breast and multidrug-resistant cancer
Vipin Saxena et al.
INTERNATIONAL JOURNAL OF NANOMEDICINE (2012)
Exploratory Analyses of Efficacy Data From Schizophrenia Trials in Support of New Drug Applications Submitted to the US Food and Drug Administration
Ni A. Khin et al.
JOURNAL OF CLINICAL PSYCHIATRY (2012)
Microvesicles and exosomes: Opportunities for cell-derived membrane vesicles in drug delivery
Susan M. van Dommelen et al.
JOURNAL OF CONTROLLED RELEASE (2012)
Delivery of P-glycoprotein substrates using chemosensitizers and nanotechnology for selective and efficient therapeutic outcomes
Rita Nieto Montesinos et al.
JOURNAL OF CONTROLLED RELEASE (2012)
Structural Modifications that Alter the P-Glycoprotein Efflux Properties of Compounds
Stephen A. Hitchcock
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Synergistic effect of folate-mediated targeting and verapamil-mediated P-gp inhibition with paclitaxel -polymer micelles to overcome multi-drug resistance
Feihu Wang et al.
BIOMATERIALS (2011)
The mechanism of enhancement on oral absorption of paclitaxel by N-octyl-O-sulfate chitosan micelles
Ran Mo et al.
BIOMATERIALS (2011)
Design and engineering of nanogels for cancer treatment
Murali Mohan Yallapu et al.
DRUG DISCOVERY TODAY (2011)
Excipients enhance intestinal absorption of ganciclovir by P-gp inhibition: Assessed in vitro by everted gut sac and in situ by improved intestinal perfusion
Ming Li et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2011)
Influence of intestinal efflux pumps on the absorption and transport of furosemide
Abdullah M. Al-Mohizea
SAUDI PHARMACEUTICAL JOURNAL (2011)
Transferrin-conjugated nanoparticles of Poly(lactide)-D-α-Tocopheryl polyethylene glycol succinate diblock copolymer for targeted drug delivery across the blood-brain barrier
Chee Wee Gan et al.
BIOMATERIALS (2010)
Reciprocal competition between lipid nanocapsules and P-gp for paclitaxel transport across Caco-2 cells
E. Roger et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2010)
Design and in vitro evaluation of a novel polymeric P-glycoprotein (P-gp) inhibitor
Javed Iqbal et al.
JOURNAL OF CONTROLLED RELEASE (2010)
Schizophrenia and Borderline Personality Disorder Similarities and Differences in the Experience of Auditory Hallucinations, Paranoia, and Childhood Trauma
David G. Kingdon et al.
JOURNAL OF NERVOUS AND MENTAL DISEASE (2010)
The environment and schizophrenia
Jim van Os et al.
NATURE (2010)
Approaches to transport therapeutic drugs across the blood-brain barrier to treat brain diseases
Reinhard Gabathuler
NEUROBIOLOGY OF DISEASE (2010)
Uptake and binding of the serotonin 5-HT1A antagonist [18F]-MPPF in brain of rats: Effects of the novel P-glycoprotein inhibitor tariquidar
Christian la Fougere et al.
NEUROIMAGE (2010)
Regional increase in P-glycoprotein function in the blood-brain barrier of patients with chronic schizophrenia: A PET study with [11C]verapamil as a probe for P-glycoprotein function
Onno L. de Klerk et al.
PSYCHIATRY RESEARCH-NEUROIMAGING (2010)
Nanoparticles as Novel Carrier for Brain Delivery: A Review
Abhinav Agarwal et al.
CURRENT PHARMACEUTICAL DESIGN (2009)
Novel formulation approaches for optimising delivery of anticancer drugs based on P-glycoprotein modulation
Tripta Bansal et al.
DRUG DISCOVERY TODAY (2009)
Dendrimers as versatile platform in drug delivery applications
Sonke Svenson
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS (2009)
Novel double coated nanocapsules for intestinal delivery and enhanced oral bioavailability of tacrolimus, a P-gp substrate drug
Taher Nassar et al.
JOURNAL OF CONTROLLED RELEASE (2009)
Intestinal Breast Cancer Resistance Protein (BCRP)/Bcrp1 and Multidrug Resistance Protein 3 (MRP3)/Mrp3 Are Involved in the Pharmacokinetics of Resveratrol
Koen van de Wetering et al.
MOLECULAR PHARMACOLOGY (2009)
Blood-brain barrier P-glycoprotein function decreases in specific brain regions with aging: A possible role in progressive neurodegeneration
Anna L. Bartels et al.
NEUROBIOLOGY OF AGING (2009)
Review: Role of developmental inflammation and blood-brain barrier dysfunction in neurodevelopmental and neurodegenerative diseases
H. B. Stolp et al.
NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY (2009)
Identification of Novel Specific and General Inhibitors of the Three Major Human ATP-Binding Cassette Transporters P-gp, BCRP and MRP2 Among Registered Drugs
Par Matsson et al.
PHARMACEUTICAL RESEARCH (2009)
Aripiprazole brain concentration is altered in P-glycoprotein deficient mice
Jun-Sheng Wang et al.
SCHIZOPHRENIA RESEARCH (2009)
Schizophrenia, just the facts 4. Clinical features and conceptualization
Rajiv Tandon et al.
SCHIZOPHRENIA RESEARCH (2009)
Structure of P-Glycoprotein Reveals a Molecular Basis for Poly-Specific Drug Binding
Stephen G. Aller et al.
SCIENCE (2009)
Poly (D, L-Lactide) Nanosuspensions of Risperidone for Parenteral Delivery: Formulation and In-Vitro Evaluation
M. Muthu et al.
Current Drug Delivery (2009)
Pharmacodynamic consequences of P-glycoprotein-dependent pharmacokinetics of risperidone and haloperidol in mice
Katrin M. Kirschbaum et al.
BEHAVIOURAL BRAIN RESEARCH (2008)
Differential pharmacological regulation of drug efflux and pharmacoresistant schizophrenia
Mary Bebawy et al.
BIOESSAYS (2008)
A critical overview of the influence of inflammation and infection on P-glycoprotein expression and activity in the brain
Derek J. Roberts et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2008)
Potential of solid lipid nanoparticles in brain targeting
Indu Pal Kaur et al.
JOURNAL OF CONTROLLED RELEASE (2008)
Decreased blood-brain barrier P-glycoprotein function in the progression of Parkinson's disease, PSP and MSA
A. L. Bartels et al.
JOURNAL OF NEURAL TRANSMISSION (2008)
Thiolated chitosans: useful excipients for oral drug delivery
Martin Werle et al.
JOURNAL OF PHARMACY AND PHARMACOLOGY (2008)
Modulation of P-glycoprotein at the blood-brain barrier: Opportunities to improve central nervous system pharmacotherapy
David S. Miller et al.
PHARMACOLOGICAL REVIEWS (2008)
In vitro P-glycoprotein assays to predict the in vivo interactions of P-glycoprotein with drugs in the central nervous system
Bo Feng et al.
DRUG METABOLISM AND DISPOSITION (2008)
Natural and synthetic polymers as inhibitors of drug efflux pumps
Martin Werle
PHARMACEUTICAL RESEARCH (2008)
Surfactant-polymer nanoparticles overcome P-glycoprotein-mediated drug efflux
Mahesh D. Chavanpatil et al.
MOLECULAR PHARMACEUTICS (2007)
Solid lipid nanoparticles for targeted brain drug delivery
Paolo Blasi et al.
ADVANCED DRUG DELIVERY REVIEWS (2007)
Lipid formulation strategies for enhancing intestinal transport and absorption of P-glycoprotein (P-gp) substrate drugs:: In vitro/in vivo case studies
Panayiotis P. Constantinides et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2007)
Effect of nanoparticulate polybutylcyanoacrylate and methylmethacrylate-sulfopropylmethacrylate on the permeability of zidovudine and lamivudine across the in vitro blood-brain barrier
Yung-Chih Kuo et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2006)
Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new Polymer-Lipid Hybrid Nanoparticles (PLN) for enhanced treatment of multidrug-resistant breast cancer
Ho Lun Wong et al.
JOURNAL OF CONTROLLED RELEASE (2006)
Multifunctional polymeric micelles as cancer-targeted, MRI-ultrasensitive drug delivery systems
Norased Nasongkla et al.
NANO LETTERS (2006)
The relationship between P-glycoprotein (PGP) polymorphisms and response to olanzapine treatment in schizophrenia
Ying-Chi Lin et al.
THERAPEUTIC DRUG MONITORING (2006)
Pegylated nanocapsules produced by an organic solvent-free method:: Evaluation of their stealth properties
Arnaud Beduneau et al.
PHARMACEUTICAL RESEARCH (2006)
Cyclosporine A (CsA) affects the pharmacodynamics and pharmacokinetics of the atypical antipsychotic amisulpride probably via inhibition of P-glycoprotein (P-gp)
U. Schmitt et al.
JOURNAL OF NEURAL TRANSMISSION (2006)
Differential in vivo sensitivity to inhibition of P-glycoprotein located in lymphocytes, testes, and the blood-brain barrier
Edna F. Choo et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2006)
Etoposide nanocarriers suppress glioma cell growth by intracellular drug delivery and simultaneous P-glycoprotein inhibiltion
A Lamprecht et al.
JOURNAL OF CONTROLLED RELEASE (2006)
Modulation of intestinal P-glycoprotein function by polyethylene glycols and their derivatives by in vitro transport and in situ absorption studies
Q Shen et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2006)
Glutathione and thiolated chitosan inhibit multidrug resistance P-glycoprotein activity in excised small intestine
M Werle et al.
JOURNAL OF CONTROLLED RELEASE (2006)
Expression and function of efflux drug transporters in the intestine
M Takano et al.
PHARMACOLOGY & THERAPEUTICS (2006)
Immunosuppressors and reversion of multidrug-resistance
N Aouali et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2005)
Drug resistance in brain diseases and the role of drug efflux transporters
W Löscher et al.
NATURE REVIEWS NEUROSCIENCE (2005)
Effect of verapamil on pharmacokinetics and pharmacodynamics of risperidone: In vivo evidence of involvement of P-glycoprotein in risperidone disposition
T Nakagami et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2005)
The blood-brain barrier/neurovascular unit in health and disease
BT Hawkins et al.
PHARMACOLOGICAL REVIEWS (2005)
Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases
W Löscher et al.
PROGRESS IN NEUROBIOLOGY (2005)
Dendrimers and dendritic polymers in drug delivery
ER Gillies et al.
DRUG DISCOVERY TODAY (2005)
The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: Evaluation using the MDR1A/1B knockout mouse model
A Doran et al.
DRUG METABOLISM AND DISPOSITION (2005)
The use of a dendrimer-propranolol prodrug to bypass efflux transporters and enhance oral bioavailability
A D'Emanuele et al.
JOURNAL OF CONTROLLED RELEASE (2004)
Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds -: implications for pharmaccokinetics of selected substrates
AA El Ela et al.
JOURNAL OF PHARMACY AND PHARMACOLOGY (2004)
The brain entry of risperidone and 9-hydroxyrisperidone is greatly limited by P-glycoprotein
JS Wang et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2004)
Effect of pluronic p85 on ATPase activity of drug efflux transporters
EV Batrakova et al.
PHARMACEUTICAL RESEARCH (2004)
PET studies on P-glycoprotein function in the blood-brain barrier: How it affects uptake and binding of drugs within the CNS
PH Elsinga et al.
CURRENT PHARMACEUTICAL DESIGN (2004)
P-glycoprotein inhibitors and their screening: a perspective from bioavailability enhancement
MVS Varma et al.
PHARMACOLOGICAL RESEARCH (2003)
Thiolated polymers-thiomers:: synthesis and in vitro evaluation of chitosan-2-iminothiolane conjugates
A Bernkop-Schnürch et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2003)
Three-dimensional structures of the mammalian multidrug resistance P-glycoprotein demonstrate major conformational changes in the transmembrane domains upon nucleotide binding
MF Rosenberg et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Modeling of intestinal drug absorption: Roles of transporters and metabolic enzymes (for the Gillette Review Series)
KS Pang
DRUG METABOLISM AND DISPOSITION (2003)
Enhanced oral bioavailability of paclitaxel by coadministration of the P-glycoprotein inhibitor KR30031
JS Woo et al.
PHARMACEUTICAL RESEARCH (2003)
Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs
KMM Doan et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2002)
Effects of nonionic surfactants on membrane transporters in Caco-2 cell monolayers
BD Rege et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2002)
Effects of poly(ethylene glycol) on efflux transporter activity in Caco-2 cell monolayers
ED Hugger et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2002)
Drug delivery to brain via the blood-brain barrier
JM Scherrmann
VASCULAR PHARMACOLOGY (2002)
Drug transport to the brain:: Key roles for the efflux pump P-glycoprotein in the blood-brain barrier
M Demeule et al.
VASCULAR PHARMACOLOGY (2002)
In vitro P-glycoprotein affinity for atypical and conventional antipsychotics
DW Boulton et al.
LIFE SCIENCES (2002)
By-passing of P-glycoprotein using immunoliposomes
J Huwyler et al.
JOURNAL OF DRUG TARGETING (2002)
The impact of efflux transporters in the brain on the development of drugs for CNS disorders
EM Taylor
CLINICAL PHARMACOKINETICS (2002)
The mechanism of action of multidrug-resistance-linked P-glycoprotein
ZE Sauna et al.
JOURNAL OF BIOENERGETICS AND BIOMEMBRANES (2001)
Intestinal drug efflux: formulation and food effects
D Wagner et al.
ADVANCED DRUG DELIVERY REVIEWS (2001)
Culture and schizophrenia and other psychotic disorders
P Kulhara et al.
PSYCHIATRIC CLINICS OF NORTH AMERICA (2001)